Abstracts tagged "Comorbidity"

Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…
Abstract Number: 1049 • ACR Convergence 2021
Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have an increased burden of multimorbidity. Age is strongly associated with accumulation of comorbidities. Patients with SLE may…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 1102 • ACR Convergence 2021
Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
David Faz-Muñoz, Eduardo Martin-Nares, Alejandra Hernández-Delgado and Gabriela Hernandez-Molina, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The frequency and types of comorbidities, causes of hospitalization, and the differences among clinical phenotypes in patients with IgG4-related disease (IgG4-RD) have not been…
Abstract Number: 1924 • ACR Convergence 2021
Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utilization and Mortality in Rheumatoid Arthritis Within Independent Real-World Datasets
Bryant England¹, Yangyuna Yang¹, Punyasha Roul¹, Christian Haas², Harlan Sayles¹, Fang Yu¹, Brian Sauer³, Joshua Baker⁴, Kaleb Michaud¹, Jeffrey Curtis⁵ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Omaha, Omaha, NE, ³University of Utah, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) leads to substantial healthcare utilization and premature mortality. Prior work has demonstrated that the overlapping presence of comorbid chronic conditions, termed…
Abstract Number: 0396 • ACR Convergence 2021
Esophageal Involvement and Gastroesophageal Reflux Disease in Patients with SSc-ILD: Data from a Sub-Study of the SENSCIS Trial
Michael Kreuter¹, Dinesh Khanna², Christopher Ryerson³, Stephen Humphries⁴, Tohru Takeuchi⁵, Mark Hamblin⁶, Dag Wormanns⁷, Carina Ittrich⁸, Frank Risse⁸, Margarida Alves⁹ and David Lynch⁴, ¹Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, ²University of Michigan, Ann Arbor, MI, ³Department of Medicine & Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, Vancouver, BC, Canada, ⁴Department of Radiology, National Jewish Health, Denver, CO, ⁵Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶University of Kansas Hospital, Kansas City, KS, ⁷Evangelische Lungenklinik, Berlin, Germany, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany
Background/Purpose: Upper gastrointestinal involvement such as esophageal dilation is frequently observed in patients with SSc-ILD and may be associated with the presence or severity of…
Abstract Number: 1123 • ACR Convergence 2021
“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
Lauren King¹, Esther Waugh¹, Crystal McKay¹, Ian Stanaitis² and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: The links between osteoarthritis (OA) and other common chronic conditions, such as type 2 diabetes mellitus (T2DM), are increasingly being appreciated in epidemiological studies.…
Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Jay Lin¹, Carrie Nielson¹, Mary Oates¹, Cynthia Deignan² and Zhigang Yu¹, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Agoura Hills, CA
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…
Abstract Number: 1198 • ACR Convergence 2021
Ultrasonography of the Median Nerve in Patients with Rheumatoid Arthritis Under Suspicion of Carpal Tunnel Syndrome
Styliani Tsiami¹, Efthymia Ntasiou², Christos Krogias², Ralf Gold², Jürgen Braun¹, Michael Sarholz³ and Xenofon Baraliakos¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Josef-Hospital, Bochum and Ruhr-University Bochum, Germany, Bochum, Germany, ³Klinik fuer Rheumatologie, St. Marien-Hospital Vreden, Vreden, Germany
Background/Purpose: Carpal tunnel syndrome (CTS) is the most common nerve compression syndrome and a common extra-articular manifestation of rheumatoid arthritis (RA). Different causes of CTS…
Abstract Number: 0483 • ACR Convergence 2021
Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
Tuhina Neogi¹, Andrea Dell'isola², Martin Englund² and Aleksandra Turkiewicz², ¹Boston University School of Medicine, Boston, MA, ²Lund University, Lund, Sweden
Background/Purpose: Oral NSAIDs are recommended for OA management. However, many patients with OA have contraindications to NSAIDs or have comorbidities that warrant precaution. Because few…
Abstract Number: 1309 • ACR Convergence 2021
Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS
Mara ngeles Puche Larrubia¹, M.Lourdes Ladehesa-Pineda¹, Pilar Font², Alejandro Escudero Contreras³, Eduardo Collantes-Estevez² and Clementina López Medina⁴, ¹Hospital Universitario Reina Sofía, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³Hospital Universitario Reina Sofía/IMIBIC/Universidad de Córdoba., Cordoba, Spain, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: a) To evaluate the impact of the number of comorbidities on the outcome measures after two years of follow-up in patients with ankylosing spondylitis…
Abstract Number: 0494 • ACR Convergence 2021
The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
Sharon Dowell¹, Huifeng Yun², Jeffrey Curtis³, Lang Chen⁴, Manuela Pedra-Nobre⁵, Dianne Wollaston⁶, SAWSAN NAJMEY⁷, Cynthia Lawrence-Elliott⁸, Theresa Lawrence-Ford⁹, Heather North¹⁰, Robin Dore¹¹, Soha Dolatabadi¹², Thaila Ramanujam¹³, Anne Winkler¹⁴, Stacy Kennedy¹⁵, Stephanie Ott¹⁶, Stephanie Ledbetter¹⁷, Grace Wright¹⁸ and Gail Kerr¹⁹, ¹Howard University College of Medicine, Washington, DC, ²University of Alabama Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama, Birmingham, AL, ⁵North Jersey Rheum. Center, Westfield, NJ, ⁶Memorial Advanced Rheumatology, Houston, TX, ⁷Midstate Rheumatology Center, PA, Freehold, NJ, ⁸North Georgia Rheum Group, Atlanta, GA, ⁹North Georgia Rheum Group, Atlanta, MD, ¹⁰Pardee UNC, Hendersonville, NC, ¹¹Robin K. Dore, MD Inc, Tustin, CA, ¹²Soha Dolatabadi, MD, Los Angeles, CA, ¹³Santa Cruz Rheumatology, Inc., Santa Cruz, CA, ¹⁴Winkler Medical Practice, Springfield, MO, ¹⁵Rowan Diagnostic Clinic, Concord, NC, ¹⁶Fairfield Medical Center, Carroll, OH, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ¹⁹Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…
Abstract Number: 1313 • ACR Convergence 2021
The Impact of Comorbidities on Patients with Axial Spondyloarthritis: A Cluster Analysis
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Hoon-Suk Cha, Eun-Mi Koh and Jaejoon Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous study using cluster analysis technique analyzed the association between comorbidities and various outcome measures in patients with axial spondyloarthritis (axSpA). Due to the…
Abstract Number: 0002 • ACR Convergence 2020
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
Cristiano Moura¹, Marina Machado¹, Celline Almeida-Brasil¹, Jeffrey R Curtis², Kevin Winthrop³, Michal Abrahamowicz¹ and Sasha Bernatsky⁴, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Oregon Health & Science University, Portland, OR, ⁴The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…

« Previous Page
1
…
8
9
10
11
12
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].